InspireMD Q1 2024 GAAP EPS $(0.21) Misses $(0.15) Estimate, Sales $1.511B Beat $1.384M Estimate
Portfolio Pulse from Benzinga Newsdesk
InspireMD reported Q1 2024 GAAP EPS of $(0.21), missing estimates by 40% but improved from last year's $(0.53). Sales reached $1.511B, significantly beating the $1.384M estimate with a 121.85K% increase from the previous year.
May 14, 2024 | 10:27 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
InspireMD's Q1 2024 earnings missed EPS estimates but showed significant sales growth, indicating potential for stock volatility but also investor optimism due to revenue increase.
The miss on EPS estimates could initially disappoint investors, potentially leading to short-term stock price volatility. However, the substantial beat on sales estimates and the dramatic year-over-year revenue growth suggest a strong underlying business performance, which could counterbalance the negative EPS impact and lead to investor optimism in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100